NDA Updates, Signed Agreements, Awarded Patents, and Clinical Study Results - Research Report on Merck, Bristol-Myers Squibb,

NDA Updates, Signed Agreements, Awarded Patents, and Clinical Study Results -
 Research Report on Merck, Bristol-Myers Squibb, Amarin, GlaxoSmithKline, and
                                    Sanofi

PR Newswire

NEW YORK, September 17, 2013

NEW YORK, September 17, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Merck &
Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), Amarin
Corporation plc (NASDAQ: AMRN), GlaxoSmithKline plc (NYSE: GSK), and Sanofi SA
(NYSE: SNY). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Merck & Co., Inc. Research Report 

On September 9, 2013, Merck & Co., Inc. (Merck) announced that it has entered
into a multi-year agreement with Israel's Maccabi Healthcare Services
(Maccabi) to leverage real-world data from Maccabi's unique longitudinal
database to inform novel, patient-centered health approaches. The

Company informed that under the terms of the agreement, the duos will apply
technical and information research capabilities to draw insights from
Maccabi's data to support personalized health care delivery strategies across
several therapeutic areas, including prevalent and costly chronic diseases.
Varda Shalev, M.D., Director of Primary Care Division at Maccabi, said, "We
believe that combining Merck research expertise with our fully integrated,
electronic, de-identified patient data can unlock major insights for achieving
better outcomes in healthcare, including chronic diseases where education,
medication and adherence are so important. Our goal is that our data will
enable research projects that advance healthcare, from product development to
patient wellness programs." The Full Research Report on Merck & Co., Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/430d_MRK]

--

Bristol-Myers Squibb Company Research Report

On September 12, 2013, Bristol-Myers Squibb Company (Bristol-Myers) announced
the results from its Phase 3 trial of Yervoy (Ipilimumab) in
previously-treated castration-resistant prostate cancer. According to the
Company, in its Phase 3 randomized, double-blind clinical trial, the Company
compared Yervoy 10 mg/kg to placebo following radiation in patients with
advanced metastatic castration-resistant prostate cancer (mCRPC) who have
received prior treatment with docetaxel. The Company informed that the study's
primary endpoint of overall survival (OS) didn't reach statistical
significance; however, it noted anti-tumor activity across some efficacy
endpoints. Bristol-Myers further informed that it will present the data at the
2013 European Cancer Congress on September 28, 2013. The Full Research Report
on Bristol-Myers Squibb Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/81a9_BMY]

--

Amarin Corporation plc Research Report

On September 9, 2013, Amarin Corporation plc (Amarin) announced that it
presently has 30 patents issued or allowed by the US Patent and Trademark
Office (USPTO), in relation to its flagship product, Vascepa (icosapent ethyl)
capsules. The Company informed that it has recently received Notices of
Allowance for US Patent Application Serial Number 13/777,398, 13/768,897, and
13/768,869, each titled Stable Pharmaceutical Composition and Methods of Using
Same. "With 30 patents issued and allowed and over 30 additional applications
pending in the United States, Amarin now has one of the most extensive, and
expanding, patent portfolios covering a product in the industry," said Joseph
Zakrzewski, Chairman and CEO of Amarin. "The continued issuance of a variety
of patents covering Vascepa is emblematic of the success achieved atAmarin
toward its goal of protecting the commercial potential of Vascepa to beyond
2030 through patent protection. In addition, Amarin'sVascepa is also
protected by trade secrets and existing manufacturing barriers to entry, along
with anticipated three- or five-year regulatory exclusivity inthe United
States." The Full Research Report on Amarin Corporation plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7cf9_AMRN]

--

GlaxoSmithKline plc Research Report 

On September 10, 2013, GlaxoSmithKline plc (GlaxoSmithKline), together with
Theravance, Inc. (Theravance), announced that the Pulmonary-Allergy Drugs
Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) has
recommended approval of umeclidinium/vilanterol for the treatment of chronic
obstructive pulmonary disease (COPD), in the US. According to the Company, a
majority of the FDA Advisory Committee is of the opinion that the efficacy and
safety provide substantial evidence to support approval of
umeclidinium/vilanterol (UMEC/VI, 62.5/25mcg dose) for the long-term,
once-daily, maintenance bronchodilator treatment of airflow obstruction in
patients with COPD. The Company informed that the proposed proprietary name
for UMEC/VI will be ANORO ELLIPTA. Patrick Vallance, President of
Pharmaceuticals R&D at GlaxoSmithKline, said, "Today's recommendation is good
news and a reflection of our commitment to giving an alternative treatment
option for patients living with COPD - a disease that affects millions of
Americans. If approved, Anoro Ellipta will be the first, once-daily dual
bronchodilator available in the US, marking another significant milestone for
GSK's portfolio of medicines to treat respiratory disease. We will continue to
work with the FDA as they complete their review." The Full Research Report on
GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/2a35_GSK]

--

Sanofi SA Research Report 

On September 12, 2013, Sanofi SA (Sanofi) announced its decision to withdraw
the lixisenatide New Drug Application (NDA) in the US, which included early
interim results from the ongoing ELIXA cardiovascular (CV) outcomes study. The
Company informed that it plans to resubmit the NDA for lixisenatide in 2015,
upon completion of the ELIXA CV study. According to Sanofi, the decision
follows a discussion with the US Food and Drug Administration (FDA) regarding
its proposed process for the review of interim data. The Company also believes
that potential public disclosure of early interim data could potentially
compromise the integrity of the ongoing ELIXA study. The Full Research Report
on Sanofi SA - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/29ea_SNY]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)